Indication statements
Nutropin AQ and Nutropin are indicated for the long-term treatment of growth failure due to a lack of adequate endogenous GH secretion.Nutropin AQ and Nutropin are also indicated for the treatment of growth failure associated with chronic renal insufficiency up to the time of renal transplantation. Nutropin and Nutropin AQ therapy should be used in conjunction with optimal management of chronic renal insufficiency.
Nutropin AQ and Nutropin are also indicated for the long-term treatment of short stature associated with Turner syndrome.
Nutropin AQ and Nutropin are also indicated for the long-term treatment of idiopathic short stature, also called non-growth hormone-deficient short stature, defined by height SDS <-2.25, and associated with growth rates unlikely to permit attainment of adult height in the normal range, in pediatric patients whose epiphyses are not closed and for whom diagnostic evaluation excludes other causes associated with short stature that should be observed or treated by other means.
Nutropin AQ and Nutropin are indicated for the replacement of endogenous GH in patients with adult GH deficiency who meet either of the following two criteria:
- Biochemical diagnosis of AGHD by means of a subnormal response to a standard GH stimulation test (peak GH <5 µg/L), and
- Adult-onset: Patients who have AGHD either alone or
with multiple hormone deficiencies (hypopituitarism) as a
result of pituitary disease, hypothalamic disease,
surgery, radiation therapy, or trauma; or
Childhood-onset: Patients who were GH-deficient during childhood, confirmed as an adult before replacement therapy with Nutropin is started
